Teplizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Teplizumab: From Type 1 Diabetes (Delay of Onset) to Diabetic Cataract
One-Sentence Summary
Teplizumab is an anti-CD3 monoclonal antibody, known for its use in delaying the onset of Type 1 diabetes mellitus through immune modulation and regulatory T-cell induction. The TxGNN model predicts it may be effective for Diabetic Cataract, but this direction is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself flags the mechanistic link as a likely knowledge-graph false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 1 diabetes mellitus (delay of onset) — not yet EU-authorized |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.38% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available from DrugBank for this evaluation. Based on known drug information, Teplizumab is an anti-CD3 monoclonal antibody used to delay the onset of Type 1 diabetes mellitus through an immune-modulatory mechanism (induction of regulatory T-cells).
The top-ranked predicted indications in this evidence pack are largely different forms of cataract (diabetic cataract, mature/immature cataract, senile cataract, cortical/nuclear cataract, tetanic cataract, craniostenosis cataract). However, the repurposing rationale accompanying each prediction explicitly assesses these links as mechanistically implausible: cataract pathophysiology is driven by lens protein denaturation, osmotic imbalance, oxidative stress, or accumulation of advanced glycation end-products — none of which are addressed by T-cell-mediated immune modulation. The evidence pack attributes the high TxGNN scores to a shared “diabetes” node in the knowledge graph connecting Teplizumab to multiple cataract subtypes, rather than a genuine causal or biological pathway. One prediction (antithrombin deficiency type 2) is even further removed, being a genetic coagulation disorder with no plausible connection to Teplizumab’s mechanism.
Given this explicit self-assessment of low biological plausibility, combined with a complete absence of supporting clinical or literature evidence, none of the top 10 predicted indications currently justify further investment without independent mechanistic validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Teplizumab currently has no EU marketing authorization (0 licenses on record; market status: Not marketed).
Safety Considerations
Please refer to the SmPC for safety information. Detailed warnings, contraindications, and drug-drug interaction data are not yet available for this compound in the current evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: All top-ranked predictions are TxGNN model output only (L5, decision stage S0) with no supporting clinical trials or literature, and the evidence pack’s own mechanistic review identifies the drug–disease link as a likely knowledge-graph false positive driven by a shared “diabetes” node rather than genuine pharmacological rationale.
To proceed, the following is needed:
- TFDA/EMA product label warnings and contraindications (currently a Blocking data gap — required before any S1 safety pre-evaluation can proceed)
- Confirmed mechanism of action (MOA) data from DrugBank to properly assess mechanistic relevance
- Independent literature or preclinical evidence directly linking anti-CD3/immune-modulatory therapy to cataract pathophysiology, given the current rationale suggests none exists
- Re-evaluation of lower-ranked or alternative predicted indications that may have stronger mechanistic grounding (e.g., autoimmune or T-cell-mediated conditions more aligned with Teplizumab’s known MOA)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.